News for Novartis AG (NVSEF)

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] The availability of the first omalizumab biosimilar will help increase access and potentially lower the healthcare cost for people with asthma and allergic diseases JERSEY CITY, N.J., March 10, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU).[2]

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now.

On March 5th, BBC reported that the US stock market had fallen after the tariffs sparked trade war fear.

Summary On February 28, 2025, Novartis AG (NVS) announced its upcoming presentations at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and W

Some of the world’s richest families are pocketing about $7 billion in a rare selling spree of their listed holdings, cashing in recent gains amid rising fears of market volatility.

Shares of Novartis AG (NVS) surged 0.56% in mid-day trading on Feb 25. The stock reached an intraday high of $112.98, before settling at $109.83, up from it

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other pharmaceutical...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why NVS stock is a Buy.

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Operator: Good morning and good afternoon, and welcome to the Novartis Q4 2024 Results Release Conference Call and Live Webcast.

Q4 Sales Growth: 16% in constant currency.Q4 Core Operating Income Growth: 29% in constant currency.Full Year Sales Growth: 12% in constant currency.Full Year

Jan 31, 2025 / 01:00PM GMTOperator Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast. (Opera

The following slide deck was published by Novartis AG in conjunction with their 2024 Q4 earnings call.

Novartis AG (NYSE:NVS) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ETCompany ParticipantsSloan Simpson - Head of IRVas Narasimhan - CEOHarry...

The major U.S. index futures are currently pointing to a higher open on Friday, with stocks likely to add to the gains posted during yesterday's volatile session.

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain related to Sandoz Group AG spin-off.

US stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings.

Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance.